close

G&CTI, premier think tank indépendant sur les thérapies avancées

G&CTI, premier think tank indépendant sur les thérapies avancées Dans l’environnement actuel où les thérapies géniques et cellulaires apparaissent certes comme une véritable révolution médicale, mais où de nombreux défis éthiques, sociétaux, politiques, économiques se posent, la quête de réponses opérationnelles s’impose ! L’ensemble des acteurs (sociétés savantes, patients, industriels,…..

Agilent to Expand State-of-the-Art Manufacturing Capacity for Nucleic Acid-Based Therapeutics

Agilent to Expand State-of-the-Art Manufacturing Capacity for Nucleic Acid-Based Therapeutics Agilent Technologies will expand its state-of-the-art production facility in Frederick, Colorado, that develops and manufactures “oligos,” which are short DNA and RNA molecules used to create nucleic acid-based therapeutics. Oligos hold the potential to be used in developing treatments for…..

Evotec – Secarna: new partnership in antisense oligonucleotide-based therapeutics

Evotec-Secarna: new partnership in antisense oligonucleotide-based therapeutics The German companies Evotec and  Secarna Pharmaceuticals have concluded a strategic partnership in the field of antisense oligonucleotide (ASO)-based therapeutics. Secarna, a global leader in discovering and developing next-generation ASO,  combines its proprietary LNAplus™ platform with cutting edge third generation LNA-chemistry to generate…..